Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IMPT-314 |
Trade Name | |
Synonyms | IMPT 314|IMPT314 |
Drug Descriptions |
IMPT-314 comprises autologous naive/memory-enriched T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and CD20 and containing a TNFRSF9 (4-1BB) co-stimulatory domain, which may induce antitumor activity (Blood (2023) 142 (Supplement 1): 6892). |
DrugClasses | CD19 Immune Cell Therapy 62 CD20 Immune Cell Therapy 11 |
CAS Registry Number | NA |
NCIT ID | C199659 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IMPT-314 | IMPT-314 | 0 | 1 |